MedPath

To measure the concentration of potentially harmful toxic heavy metals in the blood and brain fluid of patients with ALS (amyotrophic lateral sclerosis)- a lethal neurological illness – a cross-sectionalstudy

Not Applicable
Conditions
Health Condition 1: G122- Motor neuron disease
Registration Number
CTRI/2024/01/061645
Lead Sponsor
Institute Research Grant AIIMS BBSR
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Probable or Definite ALS

Exclusion Criteria

Patients where CSF cannot be done

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Estimation of Plasma and CSF levels of heavy metals in patients with ALS (amyotrophic lateral sclerosis).Timepoint: 12 months
Secondary Outcome Measures
NameTimeMethod
Comparison of CSF levels with plasma levels of heavy metals in patients with ALSTimepoint: 12 months
© Copyright 2025. All Rights Reserved by MedPath